Efficacy of Transcutaneous Electrical Stimulation Therapy in the Treatment of Overactive Bladder Developing After Stroke

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07740668

Enrollment

Registered

2026-07-31

Start date

2026-09-01

Completion date

2027-10-01

Last updated

2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder (OAB), Stroke, Tibial Nerve

Brief summary

This study is a prospective, randomized controlled clinical trial designed to evaluate the efficacy of transcutaneous electrical stimulation (posterior tibial nerve stimulation, PTNS) in the treatment of overactive bladder (OAB) developing after stroke. Primary Hypothesis: PTNS therapy will significantly improve OAB symptoms in post-stroke patients compared to standard care/sham stimulation. Primary Outcome Measure: Change from baseline in Overactive Bladder Symptom Score (OABSS) and/or frequency of urgency episodes as assessed after 12 weeks of treatment."

Detailed description

controlled clinical trial designed to evaluate the efficacy of transcutaneous electrical stimulation (posterior tibial nerve stimulation, PTNS) in the treatment of overactive bladder (OAB) developing after stroke.

Interventions

DEVICEposterior tibial nerve stimulation, PTNS

posterior tibial nerve stimulation, PTNS

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

40 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Female * Age 40 to 70 years * History of ischemic or hemorrhagic stroke at least 6 months before enrollment * Presence of overactive bladder symptoms * Ability to provide written informed consent

Exclusion criteria

* Age outside the study range * Pregnancy or breastfeeding * Active urinary tract infection * Neurogenic conditions other than stroke affecting bladder function * Inability to comply with study procedures * Refusal or inability to provide informed consent

Design outcomes

Primary

Measure	Time frame	Description
Change in daily frequency of urgency episodes	Baseline and at 12 weeks.	Number of urgency episodes per 24 hours recorded in patient bladder diary.

Secondary

Measure	Time frame	Description
Change in micturition frequency	Baseline and at 12 weeks.	Average number of micturitions per 24 hours.

Countries

Turkey (Türkiye)

Contacts

CONTACTHalil i ivelik, Assistant Professor, MD

halib_ive@hotmail.com+905423618713

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 1, 2026